146 related articles for article (PubMed ID: 6380707)
1. Selection of 9-beta-D-arabinofuranosyladenine-resistant human T-lymphoblasts with altered ribonucleotide reductase activity.
Fridland A
Cancer Res; 1984 Oct; 44(10):4328-32. PubMed ID: 6380707
[TBL] [Abstract][Full Text] [Related]
2. Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases.
Verhoef V; Sarup J; Fridland A
Cancer Res; 1981 Nov; 41(11 Pt 1):4478-83. PubMed ID: 6272978
[TBL] [Abstract][Full Text] [Related]
3. Unusual sensitivity to bleomycin and joint resistance to 9-beta-D-arabinofuranosyladenine and 1-beta-D-arabinofuranosylcytosine of mouse FM3A cell mutants with altered ribonucleotide reductase and thymidylate synthase.
Ayusawa D; Iwata K; Seno T
Cancer Res; 1983 Feb; 43(2):814-8. PubMed ID: 6184158
[TBL] [Abstract][Full Text] [Related]
4. Selection and characterization of mutant S49 T-lymphoma cell lines resistant to phosphonoformic acid: evidence for inhibition of ribonucleotide reductase.
Albert DA; Gudas LJ
J Cell Physiol; 1986 May; 127(2):281-7. PubMed ID: 2939095
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
White EL; Shaddix SC; Brockman RW; Bennett LL
Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
[TBL] [Abstract][Full Text] [Related]
6. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
Månsson E; Spasokoukotskaja T; Sällström J; Eriksson S; Albertioni F
Cancer Res; 1999 Dec; 59(23):5956-63. PubMed ID: 10606241
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
8. Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia.
Kurtzberg J; Hershfield MS
Cancer Res; 1985 Apr; 45(4):1579-86. PubMed ID: 3872167
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.
Shewach DS; Daddona PE; Ashcraft E; Mitchell BS
Cancer Res; 1985 Mar; 45(3):1008-14. PubMed ID: 3971358
[TBL] [Abstract][Full Text] [Related]
10. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
11. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
12. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
Cass CE; Selner M; Phillips JR
Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
[TBL] [Abstract][Full Text] [Related]
13. Increased level of ribonucleotide reductase and associated resistance to aphidicolin in mouse FM3A cell mutants selected for simultaneous resistance to 9-beta-D-arabinofuranosyladenine and 1-beta-D-arabinofuranosylcytosine.
Iwata K; Ayurawa D; Seno T
Gan; 1982 Apr; 73(2):167-74. PubMed ID: 6811359
[TBL] [Abstract][Full Text] [Related]
14. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
15. Relative cytotoxicity of 9-beta-D-arabinofuranosyladenine and 9-beta-D-arabinofuranosyladenine 5'-monophosphate.
Juranka P; Chan VL
Cancer Res; 1980 Nov; 40(11):4123-6. PubMed ID: 6162544
[TBL] [Abstract][Full Text] [Related]
16. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
Parker WB; Shaddix SC; Chang CH; White EL; Rose LM; Brockman RW; Shortnacy AT; Montgomery JA; Secrist JA; Bennett LL
Cancer Res; 1991 May; 51(9):2386-94. PubMed ID: 1707752
[TBL] [Abstract][Full Text] [Related]
17. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
Verhoef V; Fridland A
Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
[TBL] [Abstract][Full Text] [Related]
18. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
Plunkett W; Cohen SS
Cancer Res; 1975 Jun; 35(6):1547-54. PubMed ID: 1079475
[TBL] [Abstract][Full Text] [Related]
19. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.
Choy BK; McClarty GA; Chan AK; Thelander L; Wright JA
Cancer Res; 1988 Apr; 48(8):2029-35. PubMed ID: 2832057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
